This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2002 Oct 1;35(7):891-5.

doi: 10.1086/342563. Epub 2002 Sep 16.

Lipid formulations of amphotericins: are you a lumper or a splitter?

PMID: 12228829
DOI: 10.1086/342563

Editorial

Lipid formulations of amphotericins: are you a lumper or a splitter?

John R Wingard. Clin Infect Dis. 2002.

. 2002 Oct 1;35(7):891-5.

doi: 10.1086/342563. Epub 2002 Sep 16.

Author

PMID: 12228829
DOI: 10.1086/342563

No abstract available

PubMed Disclaimer

Comment on

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. Hughes WT, et al. Clin Infect Dis. 2002 Mar 15;34(6):730-51. doi: 10.1086/339215. Epub 2002 Feb 13. Clin Infect Dis. 2002. PMID: 11850858 No abstract available.
Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.
Frothingham R. Frothingham R. Clin Infect Dis. 2002 Oct 1;35(7):896-7; author reply 897-8. doi: 10.1086/342564. Clin Infect Dis. 2002. PMID: 12228830 No abstract available.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems